Group 1: Company Performance and Forecasts - Cambricon Technologies expects a net profit of 1.85 billion to 2.15 billion yuan in 2025, turning from loss to profit due to the rising demand for AI computing power and significant revenue growth [1] - Western Gold anticipates a net profit of 425 million to 490 million yuan for 2025, representing an increase of 46.78% to 69.23% year-on-year [6] - CICC forecasts a net profit of 8.542 billion to 10.535 billion yuan for 2025, indicating a year-on-year increase of 50% to 85% [6] - Shandong Gold expects a net profit of 4.6 billion to 4.9 billion yuan for 2025, reflecting a year-on-year increase of 56% to 66% [6] - 360 Company predicts a net profit of approximately 213 million to 318 million yuan for 2025, turning from loss to profit [6] - Changchun High-tech anticipates a net profit of 150 million to 220 million yuan for 2025, a decrease of 91% to 94% year-on-year [6] - Overseas Chinese Town A expects a net loss of 13 billion to 15.5 billion yuan for 2025 [6] Group 2: Corporate Actions and Developments - BlueFocus announced that Chairman Zhao Wenquan plans to reduce his holdings by up to 20 million shares, accounting for 0.5571% of the total share capital, due to personal financial needs [2] - Huayou Cobalt signed a cooperation framework agreement to build an integrated battery industry chain project in Indonesia, aiming to establish Indonesia as a production base for electric vehicle batteries [3] - Jihua Group's controlling shareholder is planning a change of control, leading to a temporary suspension of trading from February 2, 2026 [4] - Minexplosion Optoelectronics intends to acquire 51% of Xiamen Xizhi Precision Technology Co., becoming its controlling shareholder, which will expand its business into high-end PCB drilling [5]

Core Viewpoint - Changchun Gaoxin (000661) expects a significant decline in net profit for 2025, projecting a range of 150 million to 220 million yuan, representing a decrease of 91.48% to 94.19% compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit of 150 million to 220 million yuan for 2025, indicating a substantial decline from the previous year [1] - The increase in research and development expenses is attributed to the advancement of product development in traditional and innovative areas [1] Group 2: Product Development and Sales - The company has launched several new products, including the first domestic innovative biological agent for acute gouty arthritis, Jinbeixin (Fuxin Qibai Dantong) [1] - Efforts are ongoing to promote key products such as Jinbeixin and Meishiya, with a focus on enhancing sales promotion, terminal coverage, and channel penetration [1] Group 3: Market Adaptation and Policy Response - The company successfully included long-acting growth hormone products in the national medical insurance catalog, adapting sales policies and pricing in response to industry policy changes [2] - Adjustments in product sales policies and pricing, along with the arrangement of product delivery schedules, have led to a reduction in related revenue and net profit [2]

Core Viewpoint - Changchun Gaoxin (000661) is expected to report a significant decline in net profit for the year 2025, with projections indicating a drop of 91.48% to 94.19% compared to the previous year [1] Financial Performance - The company anticipates a net profit ranging from 150 million to 220 million yuan for 2025 [1] - The net profit excluding non-recurring gains and losses is projected to be between 437 million and 507 million yuan, reflecting a year-on-year decrease of 82.09% to 84.56% [1]

Core Viewpoint - Changchun Gaoxin (000661.SZ) expects a significant decline in net profit attributable to shareholders for 2025, projecting a range of 150 million to 220 million yuan, representing a decrease of 91.48% to 94.19% compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit of 150 million to 220 million yuan for 2025, indicating a substantial decline from the previous year [1] - The expected decline in profit is attributed to increased research and development expenses as the company advances its product pipeline [1] Group 2: Business Focus and Strategy - The company continues to focus on traditional strengths in endocrine metabolism and women's health, while also exploring innovative directions related to oncology, respiratory, and immune-related products [1] - Ongoing R&D efforts are aimed at developing differentiated products with global market potential, with several products entering clinical stages [1] Group 3: Industry Challenges - The company faces intensified competition within the industry, which is expected to impact its financial performance [1] - Changchun Baike Biotechnology Co., a subsidiary, is projected to incur losses in 2025, contributing to the overall decrease in the company's performance [1]

Core Viewpoint - Changchun Gaoxin has announced a significant decline in its expected net profit for 2025, projecting a decrease of 91.48% to 94.19% year-on-year, primarily due to increased R&D expenses and market challenges in the pharmaceutical industry [1] Group 1: Financial Projections - The company expects a net profit attributable to shareholders of 150 million to 220 million yuan for 2025, representing a year-on-year decrease of 91.48% to 94.19% [1] - The projected net profit after deducting non-recurring gains and losses is estimated to be between 437 million and 507 million yuan, reflecting a year-on-year decline of 82.09% to 84.56% [1] Group 2: Reasons for Profit Decline - Increased R&D expenses due to the company's focus on traditional areas such as endocrine metabolism and women's health, as well as innovative directions related to oncology, respiratory, and immune diseases [1] - The launch of new products, including the first domestic innovative biological agent for acute gouty arthritis, has led to increased sales and marketing expenses, necessitating a market cultivation period for new products [1] - Adjustments in sales policies and pricing in response to industry policy changes and market conditions have resulted in reduced revenue and net profit [1] - The company’s subsidiary, Changchun Baike Biotechnology Co., is expected to incur losses in 2025, further impacting overall performance [1] Group 3: Licensing Agreement - The company’s subsidiary, Shanghai Saizeng Medical Technology Co., has entered into an exclusive licensing agreement for the GenSci098 injection project, which is expected to yield a total of $1.2 billion in upfront and milestone payments [1] - The agreement includes a non-refundable upfront payment of $70 million and an additional $50 million in milestone payments, with potential for up to $1.365 billion in further milestone payments and over 10% in sales royalties post-product launch [1] - The financial impact of this licensing agreement will not be reflected in the current reporting period due to accounting policy requirements [1]

本次业绩预告的相关数据未经会计师事务所审计，公司已就业绩预告有关事 项与会计师事务所进行了预沟通，双方在业绩预告方面不存在重大分歧。 证券代码：000661 证券简称：长春高新 公告编号：2026-006 长春高新技术产业（集团）股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预告情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 | 项目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | 盈利：15,000 | 万元-22,000 | 万元 | 盈利：258,306 | 万元 | | | 比上年同期下降：91.48%-94.19% | | | | | | 扣除非经常性损益后的净利润 | 盈利：43,700 | 万元-50,700 | 万元 | 盈利：283,045 | 万元 | | | 比上年同期下 ...

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Jinsai Pharmaceutical, has received acceptance from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection for domestic production [1] Group 1: Product Information - Fuxin Qibai monoclonal antibody is a fully human anti-IL-1β monoclonal antibody that specifically blocks the binding of IL-1β to its receptor, thereby inhibiting the activation of downstream signaling pathways [1] - The drug is primarily used for the treatment of non-infectious uveitis, and there are currently no similar drugs approved for the same disease area in both domestic and international markets [1]

Group 1: Core Insights - The article discusses the recent trend of Chinese pharmaceutical companies, including Dizhe Pharmaceutical, applying for listings on the Hong Kong Stock Exchange (HKEX), marking a new wave of "A+H" listings since 2025 [1][2] - Policy support from the China Securities Regulatory Commission (CSRC) and HKEX has facilitated this trend, with measures such as fast-track approvals for A-share companies and dedicated services for tech and biotech firms [1][2] - The drive for A+H listings is also fueled by companies' need for diversified capital channels to mitigate A-share market volatility and to support significant R&D investments and international commercialization efforts [2] Group 2: Company-Specific Developments - Dizhe Pharmaceutical aims to enhance its global strategy and brand image through its HKEX listing, which is expected to attract international investors and foster collaborations with multinational pharmaceutical companies [2][4] - Despite projected revenue growth from 1 billion yuan in 2023 to 800 million yuan in 2025, Dizhe Pharmaceutical anticipates a net loss of 770 million yuan in 2025, highlighting the ongoing challenge of high R&D and sales expenses [3][5] - The company is actively advancing its core products, with ongoing clinical trials and plans to expand indications, while also focusing on improving operational efficiency and reducing sales expense ratios [4][5] Group 3: Market Trends and Challenges - The A+H listing trend is expected to continue into 2026, but there may be a significant differentiation between leading companies and mid-tier firms, with the latter facing greater pressure [3][10] - There are rumors of tightening listing requirements for HKEX, potentially raising the market capitalization threshold to 30 billion yuan, which could impact the number of companies able to list [6][7][8] - The HKEX has seen a substantial increase in IPO activity, with 117 companies listed in 2025, raising a total of 285.69 billion HKD, indicating a robust market despite potential pressures from increased supply [9][10]

Market Overview - The biopharmaceutical sector experienced a decline of 1.3% on January 29, with Hualan Vaccine leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Individual Stock Performance - Weigao Bio (002880) saw a closing price of 30.07, with an increase of 4.59% and a trading volume of 88,100 shares, totaling a transaction value of 266 million yuan [1] - Changchun High-tech (000661) closed at 98.30, up 0.92%, with a trading volume of 64,700 shares and a transaction value of 629 million yuan [1] - Other notable performers include Boya Bio (300294) and Zhifei Biological (300122), both with a closing price increase of 0.92% and 0.73% respectively [1] Declining Stocks - Hualan Bio (301207) reported a significant decline of 9.05%, closing at 22.62, with a trading volume of 300,600 shares and a transaction value of 689 million yuan [2] - Junshi Biosciences (688180) fell by 6.02%, closing at 36.82, with a trading volume of 266,100 shares and a transaction value of 1 billion yuan [2] - Other stocks such as Jinkang (688670) and Bohui Innovation (300318) also experienced declines of 5.81% and 4.95% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 866 million yuan from institutional investors, while retail investors contributed a net inflow of 682 million yuan [2] - Notable net inflows from retail investors were observed in stocks like Shanghai Laishi (002252) and Weigao Bio (002880) [3] - Conversely, stocks such as Zhixiang Quantai (688443) and Weigao Bio (002880) experienced significant net outflows from institutional and speculative investors [3]

Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received a notice of acceptance from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection, aimed at treating non-infectious uveitis [1][2]. Group 1: Drug Information - The drug Fuxin Qibai monoclonal antibody injection is a fully human anti-IL-1β monoclonal antibody developed by Jinsai Pharmaceutical, intended for the treatment of non-infectious uveitis [1][2]. - The clinical trial application has been accepted under the registration numbers CXSL2600136 and CXSL2600137, indicating a positive step towards further development [1][2]. - There are currently no similar drugs approved for the same indication in the domestic and international markets, highlighting the potential market opportunity for Fuxin Qibai [1][2]. Group 2: Disease Context - Non-infectious uveitis is a heterogeneous inflammatory disease affecting the uveal tract and surrounding tissues, with a global annual incidence rate of 17 to 52 per 100,000 and a prevalence rate of 115 to 204 per 100,000, representing a significant public health burden [2]. - Existing biological agents approved for this indication are primarily anti-TNFα drugs, with many patients experiencing inadequate response or intolerance, indicating a strong demand for safer and more effective treatment options [2]. Group 3: Company Impact - If the clinical trial progresses smoothly, it will help the company expand its business structure, optimize its product portfolio, and enhance its core competitiveness [3]. - The company is committed to actively advancing the research and development projects and will fulfill its information disclosure obligations regarding the project's progress [4].